Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study – DocWire News

This article was originally published here

Clin Immunol. 2021 Mar 5:108712. doi: 10.1016/j.clim.2021.108712. Online ahead of print.

ABSTRACT

In the past year, an emerging disease called Coronavirus disease 2019 (COVID-19), caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been discovered in Wuhan, China, which has become a worrying pandemic and has challenged the world health system and economy. SARS-CoV-2 enters the host cell through a specific receptor (Angiotensin-converting enzyme 2) expressed on epithelial cells of various tissues. The virus, by inducing cell apoptosis and production of pro-inflammatory cytokines, generates as cytokine storm, which is the major cause of mortality in the patients. This type of response, along with responses by other immune cell, such as alveolar macrophages and neutrophils causes extensive damage to infected tissue. Newly, a novel cell-based therapy by Mesenchymal stem cell (MSC) as well as by their exosomes has been developed for treatment of COVID-19 that yielded promising outcomes. In this review study, we discuss the characteristics and benefits of MSCs therapy as well as MSC-secreted exosome therapy in treatment of COVID-19 patients.

PMID:33684527 | DOI:10.1016/j.clim.2021.108712

Read this article:

Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study - DocWire News